Jennifer Visich

1.7k total citations · 1 hit paper
34 papers, 1.1k citations indexed

About

Jennifer Visich is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Hematology. According to data from OpenAlex, Jennifer Visich has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Oncology and 7 papers in Hematology. Recurrent topics in Jennifer Visich's work include Monoclonal and Polyclonal Antibodies Research (13 papers), Blood properties and coagulation (5 papers) and HER2/EGFR in Cancer Research (5 papers). Jennifer Visich is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), Blood properties and coagulation (5 papers) and HER2/EGFR in Cancer Research (5 papers). Jennifer Visich collaborates with scholars based in United States, Switzerland and United Kingdom. Jennifer Visich's co-authors include Maurício Maia, Dante J. Pieramici, Robert F. See, Kha Le, Alessandro Castellarin, Robert L. Avery, Melvin Rabena, Nathan Steinle, Stephen Couvillion and Dilsher S. Dhoot and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jennifer Visich

34 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

2014 284 citations Robert L. Avery, Alessandro Castellarin et al. British Journal of Ophthalmology profile →

Peers

Countries citing papers authored by Jennifer Visich

Since Specialization

Citations

This map shows the geographic impact of Jennifer Visich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Visich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Visich more than expected).

Fields of papers citing papers by Jennifer Visich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Visich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Visich. The network helps show where Jennifer Visich may publish in the future.

Co-authorship network of co-authors of Jennifer Visich

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Visich. A scholar is included among the top collaborators of Jennifer Visich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Visich. Jennifer Visich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors 2023 ·SHILAP Revista de lepidopterología ·David R. Spigel, Costantine Albany, Michael Chisamore, Kelly D. Moynihan, (unknown), Jennifer Visich, (unknown), Xiaohan Liu, (unknown), Andrea Pirzkall, Elizabeth I. Buchbinder	1
2	A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis 2021 ·Osteoarthritis and Cartilage ·N.E. Lane, Bang‐Gee Hsu, Jennifer Visich, (unknown), A. Khan, J. Dananberg	28
3	Safety, tolerability, pharmacokinetics, and clinical outcomes following treatment of painful knee osteoarthritis with senolytic molecule UBX0101 2020 ·Osteoarthritis and Cartilage ·Bang‐Gee Hsu, Jennifer Visich, Nancy E. Lane, (unknown), (unknown), (unknown), Rémi-Martin Laberge, J. Dananberg	13
4	Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer 2015 ·Cancer Chemotherapy and Pharmacology ·Angelica Quartino, Carina Hillenbach, Jing Li, Hanbin Li, Russell Wada, Jennifer Visich, Chunze Li, Dominik Heinzmann, Jin Y. Jin, Bert L. Lum	59
5	Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients with DME 2014 ·Investigative Ophthalmology & Visual Science ·Robert L. Avery, Alessandro Castellarin, Nathan Steinle, Dilsher S. Dhoot, Dante J. Pieramici, Robert F. See, Stephen Couvillion, (unknown), Kha Le, Jennifer Visich	2
6	Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD breakdown → 2014 ·British Journal of Ophthalmology ·Robert L. Avery, Alessandro Castellarin, Nathan Steinle, Dilsher S. Dhoot, Dante J. Pieramici, Robert F. See, Stephen Couvillion, Ma'an Nasir, Melvin Rabena, Kha Le, Maurício Maia, Jennifer Visich	284
7	Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema 2014 ·Ophthalmology ·Yi Xin Zhang, Zhenling Yao, (unknown), Peter Kuebler, Jennifer Visich, Maurício Maia, Lisa Tuomi, Jason S. Ehrlich, Roman G. Rubio, Peter A. Campochiaro	29
8	Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Amit Garg, Angelica Quartino, Jing Li, Jin Jin, Daisuke Wada, Hanbin Li, Javier Cortés, Virginia McNally, Graham Ross, Jennifer Visich, Bert L. Lum	49
9	Analysis of 24 month data from the HARBOR study indicates that anti-therapeutic antibodies status had no significant impact on the treatment response to ranibizumab 2013 ·Investigative Ophthalmology & Visual Science ·(unknown), Kha Le, Eric Wakshull, Jeriza Rusit, Jennifer Visich, Jeffrey Nau	2
10	Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy 2013 ·The AAPS Journal ·Rui Zhu, Yanan Zheng, Wendy S. Putnam, Jennifer Visich, Mark D. Eisner, John G. Matthews, Karin Rosén, David Z. D’Argenio	9
11	Pharmacokinetics (PK) Of Intravitreal Ranibizumab (RBZ) In Patients With Neovascular Age-related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), And Diabetic Macular Edema (DMD) 2012 ·Investigative Ophthalmology & Visual Science ·Lisa Tuomi, Yi Zhang, Jennifer Visich	1
12	A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis 2012 ·Gut ·Paul Rutgeerts, Richard N. Fedorak, Daan W. Hommes, Andreas Sturm, Daniel C. Baumgart, Brian Bressler, Stefan Schreiber, John Mansfield, Marna Williams, Meina Tang, Jennifer Visich, Xiaohui Wei, Mary Keir, Diana Luca, Dimitry M. Danilenko, Jackson G. Egen, Sharon O’Byrne	111
13	Pharmacokinetics and Pharmacodynamics of Anti-BR3 Monoclonal Antibody in Mice 2012 ·Pharmaceutical Research ·Anshu Marathe, Suhasini Iyer, Zhihua Qiu, Jennifer Visich, Donald E. Mager	1
14	Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia 2012 ·The Journal of Clinical Pharmacology ·Jing Li, Jianguo Zhi, Michael Wenger, Nancy Valente, Anna Dmoszyńska, Tadeusz Robak, (unknown), Amita Joshi, Jennifer Visich	64
15	Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis 2008 ·The Journal of Clinical Pharmacology ·Ivan Nestorov, Alain Munafo, Orestis Papasouliotis, Jennifer Visich	42
16	Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept 2008 ·Toxicological Sciences ·Michela Carbonatto, Ping Yu, (unknown), (unknown), Stephanie Steidler, (unknown), (unknown), (unknown), (unknown), Michele Ardizzone, Sergio Peano, Jennifer Visich, Derek B. Janszen, Stacey R. Dillon, Rafael Ponce	37
17	Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers 2007 ·European Journal of Clinical Pharmacology ·Alain Munafo, (unknown), Ivan Nestorov, Jennifer Visich, Mark Rogge	51
18	Bioavailability and relative tissue distribution of [125I]‐recombinant human thrombin following intravenous or subcutaneous administration to non‐human primates 2006 ·Journal of Thrombosis and Haemostasis ·Jennifer Visich, Kelly Byrnes-Blake, Kenneth B. Lewis, Brent Meengs, Mark Rogge	4
19	Preclinical safety of recombinant human thrombin 2006 ·Regulatory Toxicology and Pharmacology ·(unknown), Rafael Ponce, Linda A. Zuckerman, (unknown), Jennifer Visich, (unknown), Nancy A. Jenkins, (unknown), Susan Pederson, G Knitter, Thomas E. Palmer, (unknown), R. Early, Mark Rogge	23
20	Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers 2005 ·Thrombosis and Haemostasis ·Jennifer Visich, Linda A. Zuckerman, Michael D. Butine, (unknown), (unknown), (unknown), Thomas C. Reynolds	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact